Tag Archives: Emerging Companies

Emerging Company Policy Deconstructed: Start-up Jobs and Innovation Act (S. 1658)

Cancer

In a nutshell: Senators Robert Menendez (D-NJ) and Pat Toomey (R-PA) introduced the Start-up Jobs and Innovation Act to spur capital formation for R&D-focused companies in the early stages of development. Why you should care: It can take over a decade and cost more than $1 billion to bring a single groundbreaking biotechnology treatment from laboratory bench to hospital bedside, and virtually the entire process is funded by private investment. The Start-up Jobs and Innovation Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

JOBS Act Deconstructed: Confidential Filing

AB23475

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. Any company conducting a public offering must file a registration statement, called an S-1, with the SEC.  The purpose of this document is to inform investors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

JOBS Act Deconstructed: Testing-the-Waters

87881842

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act enables companies to promote themselves to potential investors in advance of their IPO. Prior to the JOBS Act, companies conducting a public offering Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. In a nutshell: The JOBS Act directs the SEC to create a new class of securities modeled after those eligible for the existing exemption under SEC Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum to Showcase NSF-funded Companies

150639480

No risk, no reward—that’s the concept driving the startups and entrepreneurs scheduled to present at next week’s 12th Annual BIO Investor Forum as a part of the newly-announced National Science Foundation (NSF) track of presenting companies. Expanding on the success of the Discovery Track Presentations, the 2013 BIO Investor Forum will feature a dedicated track of 10 NSF-funded companies focused on drug discovery, diagnostics and other related technologies. The companies are supported by the NSF Small Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,